HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by article Browse by volume    

Heroin Addiction and Related Clinical Problems: 2020, 22, N1 (pages: 7 - 8)

Mood Stabilizing Effects of Methadone in Opioid Use Disorder Patient

Gohari J., and Riaz U.

Summary: Lower doses of mood stabilizers may be necessary in patients receiving Methadone, especially when considering the metabolic syndrome and prolongation of QT interval which both Methadone and some psychoactive medications can cause. Research has shown that Methadone is a µ-opioid receptor agonist, as well as a serotonin and noradrenaline uptake inhibitor and NMDA receptor antagonist. Moreover, Methadone has the most evidence of efficacy in comorbid BD and opioid use disorder. We present here a case of a pregnant individual with a history of substance use disorder, BD-II and ADHD.

 

AU-CNS Associazione per l’Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali
Association for the Application of Neuroscientific Knowledge to Social Aims
Via XX Settembre, 83 – 55045 PIETRASANTA (Lucca) - Italy
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org		 Start of page